Research ExplorerPublicationsSwitching to Impella 5.0 decreases need for transfusion in p...

Switching to Impella 5.0 decreases need for transfusion in patients undergoing temporary mechanical circulatory support

Standard

Switching to Impella 5.0 decreases need for transfusion in patients undergoing temporary mechanical circulatory support. / Castro, Liesa; Zipfel, Svante; Braunsteiner, Josephine; Schaefer, Andreas; Sill, Björn; Söffker, Gerold; Kluge, Stefan; Lubos, Edith; Rybczinski, Meike; Grahn, Hanno; Schrage, Benedikt; Becher, Peter M; Barten, Markus J; Westermann, Dirk; Blankenberg, Stefan; Reichenspurner, Hermann; Bernhardt, Alexander M.

In: J CRIT CARE, Vol. 57, 06.2020, p. 253-258.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Castro, L, Zipfel, S, Braunsteiner, J, Schaefer, A, Sill, B, Söffker, G, Kluge, S, Lubos, E, Rybczinski, M, Grahn, H, Schrage, B, Becher, PM, Barten, MJ, Westermann, D, Blankenberg, S, Reichenspurner, H & Bernhardt, AM 2020, 'Switching to Impella 5.0 decreases need for transfusion in patients undergoing temporary mechanical circulatory support', J CRIT CARE, vol. 57, pp. 253-258. https://doi.org/10.1016/j.jcrc.2019.11.007

APA

Castro, L., Zipfel, S., Braunsteiner, J., Schaefer, A., Sill, B., Söffker, G., Kluge, S., Lubos, E., Rybczinski, M., Grahn, H., Schrage, B., Becher, P. M., Barten, M. J., Westermann, D., Blankenberg, S., Reichenspurner, H., & Bernhardt, A. M. (2020). Switching to Impella 5.0 decreases need for transfusion in patients undergoing temporary mechanical circulatory support. J CRIT CARE, 57, 253-258. https://doi.org/10.1016/j.jcrc.2019.11.007

Vancouver

Castro L, Zipfel S, Braunsteiner J, Schaefer A, Sill B, Söffker G et al. Switching to Impella 5.0 decreases need for transfusion in patients undergoing temporary mechanical circulatory support. J CRIT CARE. 2020 Jun;57:253-258. https://doi.org/10.1016/j.jcrc.2019.11.007

Bibtex

@article{7e1182115ae241f6964c27a240949b17,
title = "Switching to Impella 5.0 decreases need for transfusion in patients undergoing temporary mechanical circulatory support",
abstract = "PURPOSE: Various options of temporary mechanical circulatory support (tMCS) exist for the treatment of cardiogenic shock, however, all forms of tMCS carry a risk of complications. The aim of this study was to compare bleeding complications and thromboembolic events under extracorporeal life support + Impella 2.5/CP (ECMELLA) and isolated Impella 5.0 therapy in the same patient cohort.MATERIAL: We retrospectively analyzed data of patients who underwent ECMELLA implantation and subsequent Impella 5.0 therapy. Implantation strategy and anticoagulation protocol were comparable in both groups.RESULTS: We included 15 patients (mean age 57.2 years; 80% of male patients) who were weaned from ECMELLA undergoing subsequent Impella 5.0 implantation. Mean duration of ECMELLA and Impella 5.0 therapy (10.5 vs. 11.2 days) did not differ significantly (p = .731). The average number of transfused packed red blood cells (PRBC) and thrombocyte concentrates (TC) was significantly decreased during Impella 5.0 treatment (PRBC: 30.3 vs 12.3, p = .001; TC: 5.9 vs 2.2, p = .045). Additionally, the transfusion rates per day were significantly reduced under Impella 5.0 support.CONCLUSIONS: The need for transfusions is significantly lower in the phase of Impella 5.0 therapy compared to the initial phase on ECMELLA. Therefore, we recommend replacing ECMELLA by an Impella 5.0 device early, if possible.",
author = "Liesa Castro and Svante Zipfel and Josephine Braunsteiner and Andreas Schaefer and Bj{\"o}rn Sill and Gerold S{\"o}ffker and Stefan Kluge and Edith Lubos and Meike Rybczinski and Hanno Grahn and Benedikt Schrage and Becher, {Peter M} and Barten, {Markus J} and Dirk Westermann and Stefan Blankenberg and Hermann Reichenspurner and Bernhardt, {Alexander M}",
note = "Copyright {\textcopyright} 2019 Elsevier Inc. All rights reserved.",
year = "2020",
month = jun,
doi = "10.1016/j.jcrc.2019.11.007",
language = "English",
volume = "57",
pages = "253--258",
journal = "J CRIT CARE",
issn = "0883-9441",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Switching to Impella 5.0 decreases need for transfusion in patients undergoing temporary mechanical circulatory support

AU - Castro, Liesa

AU - Zipfel, Svante

AU - Braunsteiner, Josephine

AU - Schaefer, Andreas

AU - Sill, Björn

AU - Söffker, Gerold

AU - Kluge, Stefan

AU - Lubos, Edith

AU - Rybczinski, Meike

AU - Grahn, Hanno

AU - Schrage, Benedikt

AU - Becher, Peter M

AU - Barten, Markus J

AU - Westermann, Dirk

AU - Blankenberg, Stefan

AU - Reichenspurner, Hermann

AU - Bernhardt, Alexander M

N1 - Copyright © 2019 Elsevier Inc. All rights reserved.

PY - 2020/6

Y1 - 2020/6

N2 - PURPOSE: Various options of temporary mechanical circulatory support (tMCS) exist for the treatment of cardiogenic shock, however, all forms of tMCS carry a risk of complications. The aim of this study was to compare bleeding complications and thromboembolic events under extracorporeal life support + Impella 2.5/CP (ECMELLA) and isolated Impella 5.0 therapy in the same patient cohort.MATERIAL: We retrospectively analyzed data of patients who underwent ECMELLA implantation and subsequent Impella 5.0 therapy. Implantation strategy and anticoagulation protocol were comparable in both groups.RESULTS: We included 15 patients (mean age 57.2 years; 80% of male patients) who were weaned from ECMELLA undergoing subsequent Impella 5.0 implantation. Mean duration of ECMELLA and Impella 5.0 therapy (10.5 vs. 11.2 days) did not differ significantly (p = .731). The average number of transfused packed red blood cells (PRBC) and thrombocyte concentrates (TC) was significantly decreased during Impella 5.0 treatment (PRBC: 30.3 vs 12.3, p = .001; TC: 5.9 vs 2.2, p = .045). Additionally, the transfusion rates per day were significantly reduced under Impella 5.0 support.CONCLUSIONS: The need for transfusions is significantly lower in the phase of Impella 5.0 therapy compared to the initial phase on ECMELLA. Therefore, we recommend replacing ECMELLA by an Impella 5.0 device early, if possible.

AB - PURPOSE: Various options of temporary mechanical circulatory support (tMCS) exist for the treatment of cardiogenic shock, however, all forms of tMCS carry a risk of complications. The aim of this study was to compare bleeding complications and thromboembolic events under extracorporeal life support + Impella 2.5/CP (ECMELLA) and isolated Impella 5.0 therapy in the same patient cohort.MATERIAL: We retrospectively analyzed data of patients who underwent ECMELLA implantation and subsequent Impella 5.0 therapy. Implantation strategy and anticoagulation protocol were comparable in both groups.RESULTS: We included 15 patients (mean age 57.2 years; 80% of male patients) who were weaned from ECMELLA undergoing subsequent Impella 5.0 implantation. Mean duration of ECMELLA and Impella 5.0 therapy (10.5 vs. 11.2 days) did not differ significantly (p = .731). The average number of transfused packed red blood cells (PRBC) and thrombocyte concentrates (TC) was significantly decreased during Impella 5.0 treatment (PRBC: 30.3 vs 12.3, p = .001; TC: 5.9 vs 2.2, p = .045). Additionally, the transfusion rates per day were significantly reduced under Impella 5.0 support.CONCLUSIONS: The need for transfusions is significantly lower in the phase of Impella 5.0 therapy compared to the initial phase on ECMELLA. Therefore, we recommend replacing ECMELLA by an Impella 5.0 device early, if possible.

U2 - 10.1016/j.jcrc.2019.11.007

DO - 10.1016/j.jcrc.2019.11.007

M3 - SCORING: Journal article

C2 - 32423622

VL - 57

SP - 253

EP - 258

JO - J CRIT CARE

JF - J CRIT CARE

SN - 0883-9441

ER -